HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.

AbstractOBJECTIVE:
To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).
DATA SOURCES:
A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant information.
STUDY SELECTION:
All English-language articles from 2004 to May 2015 appearing in these searches were reviewed for relevance to this paper. In addition, their bibliographies were reviewed to identify any articles not identified in the searches.
DATA SYNTHESIS:
CAZ/AVI is a new cephalosporin β-lactamase inhibitor combination with a spectrum of activity targeted against Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa. The dosing regimen is 2.5 g every eight hours administered via IV infusion over two hours for 5 to 14 days. The dosing regimen should be adjusted based on renal function. A phase II trial has demonstrated that clinical cure rates with CAZ/AVI plus metronidazole are comparable to those with meropenem in the treatment of adults with complicated intra-abdominal infections. Another phase II clinical trial has demonstrated that clinical cure rates with CAZ/AVI are comparable to those with imipenem/cilastatin for the treatment of adults with complicated urinary tract infections (cUTIs). CAZ/AVI has a side effect profile similar to that of cephalosporins and carbapenems.
CONCLUSION:
CAZ/AVI has a favorable efficacy and safety profile in the treatment of adults with complicated intra-abdominal infections or cUTIs. Further research is needed to refine its role, particularly for the treatment of multi-drug-resistant Gram-negative infections.
AuthorsElias B Chahine, Mariette Sourial, Raquel Ortiz
JournalThe Consultant pharmacist : the journal of the American Society of Consultant Pharmacists (Consult Pharm) Vol. 30 Issue 12 Pg. 695-705 (Dec 2015) ISSN: 0888-5109 [Print] United States
PMID26671269 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • beta-Lactamase Inhibitors
  • Ceftazidime
Topics
  • Adult
  • Anti-Bacterial Agents (administration & dosage, adverse effects, therapeutic use)
  • Azabicyclo Compounds (administration & dosage, adverse effects, therapeutic use)
  • Ceftazidime (administration & dosage, adverse effects, therapeutic use)
  • Drug Combinations
  • Gram-Negative Bacteria (drug effects)
  • Gram-Negative Bacterial Infections (drug therapy, microbiology)
  • Humans
  • Intraabdominal Infections (drug therapy, microbiology)
  • Urinary Tract Infections (drug therapy, microbiology)
  • beta-Lactamase Inhibitors (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: